Digene Infrastructure Scale-Up For DNA Pap Could Follow Failed Cytyc Merger
This article was originally published in The Gray Sheet
Executive Summary
Digene may decide to expand its sales infrastructure for marketing the HPV DNA Pap test as a primary screen for cervical cancer if its pending merger with Cytyc does not occur